SCHEMBL1732912

SCHEMBL1732912

CC(CCOc1cccc2[nH]c3ccccc3c12)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 5/20 0.54
MAPT P10636 3/20 0.53
LMNA P02545 1/20 0.53
CYP3A4 P08684 1/20 0.53
ADRB2 P07550 10/20 0.53
DNM1 Q05193 2/20 0.53
ADRB3 P13945 4/20 0.49
DRD2 P14416 3/20 0.49
ADRB1 P08588 3/20 0.49
KDM4E B2RXH2 2/20 0.49
SLC22A2 O15244 1/20 0.49
SLC22A1 O15245 1/20 0.49
MLNR O43193 1/20 0.49
NR1I2 O75469 1/20 0.49
KCNK2 O95069 1/20 0.49
ABCB11 O95342 1/20 0.49
APP P05067 1/20 0.49
ABCB1 P08183 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6562854 0.79 TLR4 (0.58) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL1731764 0.79 ADRB2 (0.55) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL1733165 0.79 KMT2A (0.54) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL1732768 0.78 ADRB2 (0.54) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL17950801 0.77 KDM4E (0.58) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL1732630 0.77 ADRB2 (0.53) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL6921193 0.77 ADRB2 (0.59) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL14046114 0.77 ADRB2 (0.61) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL7134118 0.76 ADRB2 (0.70) TLR4MAPTLMNACYP3A4ADRB2
SCHEMBL1731305 0.75 ADRB2 (0.47) TLR4MAPTLMNACYP3A4ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1852433-B1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZERIA PHARM CO LTD (JP) 2011-11-23 EP disclosed
EP-1852433-B1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZERIA PHARM CO LTD (JP) 2011-11-23 EP disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
EP-1852433-A1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Zeria Pharmaceutical Co., Ltd. (JP) 2007-11-07 EP disclosed
EP-1852433-A1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Zeria Pharmaceutical Co., Ltd. (JP) 2007-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof CEL, LIPC, CES1 TLR4 1083/4885MAPT 3871/4885LMNA 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.